USE OF A COMPOUND ANTAGONIST TO THE NK2 RECEPTORS OF NEUROKININ A FOR THE PREPARATION OF DRUGS USEFUL FOR PREVENTING AND TREATING OF SEXUAL DYSFUNCTION

1 . A method for treating a sexual dysfunction in a patient, said method comprising administering to said patient a neurokinin A NK 2 receptor antagonist selected from:

saredutant;

(+)-N-[1-[2-[2-(3,4-dichlorophenyl)-5-oxo-4-phenylmorpholin-2-yl]ethyl]-4-(3-fluorophenyl)piperidin-4-yl]acetamide; and

(+)-1′-[2-[4-benzoyl-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl]-N,N-dimethyl-1,4′-bipiperidine-4′-carboxamide;

or a pharmaceutically acceptable salt thereof.

2 . The method according to claim 1 , wherein said neurokinin A NK 2 receptor antagonist is saredutant, or a pharmaceutically acceptable salt thereof.

3 . The method according to claim 1 , wherein said neurokinin A NK 2 receptor antagonist is (+)-N-[1-[2-[2-(3,4-dichlorophenyl)-5-oxo-4-phenylmorpholin-2-yl]ethyl]-4-(3-fluorophenyl)piperidin-4-yl]acetamide, or a pharmaceutically acceptable salt thereof.

4 . The method according to claim 1 , wherein said neurokinin A NK 2 receptor antagonist is (+)-1′-[2-[4-benzoyl-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl]-N,N-dimethyl-1,4′-bipiperidine-4′-carboxamide, or a pharmaceutically acceptable salt thereof.

5 . The method according to claim 2 , wherein said sexual dysfunction is sexual desire disorder.

6 . The method according to claim 5 , wherein said sexual desire disorder is reduced sexual desire.

7 . The method according to claim 5 , wherein said sexual desire disorder is sexual aversion.

8 . The method according to claim 3 , wherein said sexual dysfunction is sexual desire disorder.

9 . The method according to claim 8 , wherein said sexual desire disorder is reduced sexual desire.

10 . The method according to claim 8 , wherein said sexual desire disorder is sexual aversion.

11 . The method according to claim 4 , wherein said sexual dysfunction is sexual desire disorder.

12 . The method according to claim 11 , wherein said sexual desire disorder is reduced sexual desire.

13 . The method according to claim 11 , wherein said sexual desire disorder is sexual aversion.

14 . The method according to claim 2 , wherein said sexual dysfunction is a sexual arousal disorder.

15 . The method according to claim 14 , wherein said sexual arousal disorder is female sexual arousal disorder.

16 . The method according to claim 14 , wherein said sexual arousal disorder is male erectile disorder.

17 . The method according to claim 3 , wherein said sexual dysfunction is sexual arousal disorder.

18 . The method according to claim 17 , wherein said sexual arousal disorder is female sexual arousal disorder.

19 . The method according to claim 17 , wherein said sexual arousal disorder is male erectile disorder.

20 . The method according to claim 4 , wherein said sexual dysfunction is sexual arousal disorder.

21 . The method according to claim 20 , wherein said sexual arousal disorder is female sexual arousal disorder.

22 . The method according to claim 20 , wherein said sexual arousal disorder is male erectile disorder.

23 . The method according to claim 2 , wherein said sexual dysfunction is an orgasmic disorder.

24 . The method according to claim 23 , wherein said orgasmic disorder is female orgasmic disorder.

25 . The method according to claim 23 , wherein said orgasmic disorder is male orgasmic disorder.

26 . The method according to claim 23 , wherein said orgasmic disorder is premature ejaculation.

27 . The method according to claim 3 , wherein said sexual dysfunction is an orgasmic disorder.

28 . The method according to claim 27 , wherein said orgasmic disorder is female orgasmic disorder.

29 . The method according to claim 27 , wherein said orgasmic disorder is male orgasmic disorder.

30 . The method according to claim 27 , wherein said orgasmic disorder is premature ejaculation.

31 . The method according to claim 4 , wherein said sexual dysfunction is an orgasmic disorder.

32 . The method according to claim 31 , wherein said orgasmic disorder is female orgasmic disorder.

33 . The method according to claim 31 , wherein said orgasmic disorder is male orgasmic disorder.

34 . The method according to claim 31 , wherein said orgasmic disorder is premature ejaculation.

35 . The method according to claim 2 , wherein said sexual dysfunction is a painful sexual disorder.

36 . The method according to claim 35 , wherein said painful sexual disorder is dyspareunia.

37 . The method according to claim 35 , wherein said painful sexual disorder is vaginismus.

38 . The method according to claim 3 , wherein said sexual dysfunction is a painful sexual disorder.

39 . The method according to claim 38 , wherein said painful sexual disorder is dyspareunia.

40 . The method according to claim 38 , wherein said painful sexual disorder is vaginismus.

41 . The method according to claim 4 , wherein said sexual dysfunction is a painful sexual disorder.

42 . The method according to claim 41 , wherein said painful sexual disorder is dyspareunia.

43 . The method according to claim 41 , wherein said painful sexual disorder is vaginismus.

44 . The method according to claim 2 , wherein said sexual dysfunction is due to a general medical condition.

45 . The method according to claim 44 , wherein said general medical condition is a depressive disorder.

46 . The method according to claim 44 , wherein said general medical condition is a major depressive disorder.

47 . The method according to claim 3 , wherein said sexual dysfunction is due to a general medical condition.

48 . The method according to claim 47 , wherein said general medical condition is a depressive disorder.

49 . The method according to claim 47 , wherein said general medical condition is a major depressive disorder.

50 . The method according to claim 4 , wherein said sexual dysfunction is due to a general medical condition.

51 . The method according to claim 50 , wherein said general medical condition is a depressive disorder.

52 . The method according to claim 50 , wherein said general medical condition is a major depressive disorder.

53 . The method according to claim 2 , wherein said sexual dysfunction is a substance-induced sexual dysfunction.

54 . The method according to claim 3 , wherein said sexual dysfunction is a substance-induced sexual dysfunction.

55 . The method according to claim 4 , wherein said sexual dysfunction is a substance-induced sexual dysfunction.

56 . The method according to claim 2 , wherein said sexual dysfunction is an unspecified sexual dysfunction.

57 . The method according to claim 3 , wherein said sexual dysfunction is an unspecified sexual dysfunction.

58 . The method according to claim 4 , wherein said sexual dysfunction is an unspecified sexual dysfunction.

59 . A pharmaceutical composition comprising a first compound and a second compound, wherein:

said first compound is a neurokinin A NK 2 receptor antagonist selected from saredutant, (+)-N-[1-[2-[2-(3,4-dichlorophenyl)-5-oxo-4-phenylmorpholin-2-yl]ethyl]-4-(3-fluorophenyl) piperidin-4-yl]acetamide, and (+)-1′-[2-[4-benzoyl-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl]-N,N-dimethyl-1,4′-bipiperidine-4′-carboxamide; or a pharmaceutically acceptable salt thereof; and

said second compound is selected from sildenafil, vardenafil, tardalafil, alprostadil, apomorphine, midrodrine, moxisylite, phentolamine, aviptadil, testosterone, dapoxetine and tobolone.

60 . A method for treating a sexual dysfunction in a patient, said method comprising administering to said patient a pharmaceutical composition according to claim 59 .

61 . A method for treating a sexual dysfunction in a patient, said method comprising administering to said patient a first compound and a second compound, wherein:

aid first compound is a neurokinin A NK 2 receptor antagonist selected from saredutant, (+)-N-[1-[2-[2-(3,4-dichlorophenyl)-5-oxo-4-phenylmorpholin-2-yl]ethyl]-4-(3-fluorophenyl) piperidin-4-yl]acetamide, and (+)-1′-[2-[4-benzoyl-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl]-N,N-dimethyl-1,4′-bipiperidine-4′-carboxamide; or a pharmaceutically acceptable salt thereof; and

said second compound is selected from sildenafil, vardenafil, tardalafil, alprostadil, apomorphine, midrodrine, moxisylite, phentolamine, aviptadil, testosterone, dapoxetine and tobolone.

62 . The method according to claim 61 , wherein said first compound and said second compound are administered simultaneously, separately, or sequentially.

63 . A kit containing a first compound and a second compound, wherein:

said first compound is a neurokinin A NK 2 receptor antagonist selected from saredutant, (+)-N-[1-[2-[2-(3,4-dichlorophenyl)-5-oxo-4-phenylmorpholin-2-yl]ethyl]-4-(3-fluorophenyl) piperidin-4-yl]acetamide, and (+)-1′-[2-[4-benzoyl-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl]-N,N-dimethyl-1,4′-bipiperidine-4′-carboxamide; or a pharmaceutically acceptable salt thereof; and

said second compound is selected from sildenafil, vardenafil, tardalafil, alprostadil, apomorphine, midrodrine, moxisylite, phentolamine, aviptadil, testosterone, dapoxetine and tobolone;

said first compound and said second compound are in separate compartments and in similar or different packagings; and

said first compound and said second compound are intended to be administered simultaneously, separately or sequentially.